FierceBiotech 2026년 4월 13일 BioNTech, SynOx plot paths to FDA as trials hit goals in competitive tumor types
FierceBiotech 2026년 2월 28일 BioNTech advances DualityBio ADC into phase 3 with half the patients of Merck-Daiichi rival